BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1271 related articles for article (PubMed ID: 18376307)

  • 41. Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
    Shiratsuchi T; Ishibashi H; Shirasuna K
    J Cell Physiol; 2002 Dec; 193(3):340-8. PubMed ID: 12384986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
    Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
    Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
    Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
    Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
    Zhang W; Ling D; Tan J; Zhang J; Li L
    Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
    Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
    Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
    He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
    Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
    Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
    Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.
    Chang MH; Kuo WW; Chen RJ; Lu MC; Tsai FJ; Kuo WH; Chen LY; Wu WJ; Huang CY; Chu CH
    J Mol Endocrinol; 2008 Aug; 41(2):65-74. PubMed ID: 18495691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
    Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development.
    Teesalu T; Blasi F; Talarico D
    Dev Dyn; 1998 Sep; 213(1):27-38. PubMed ID: 9733098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
    Li YJ; Zheng BZ; Zhou ZL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
    Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
    Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
    Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
    Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
    Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
    J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
    Mazumdar A; Adam L; Boyd D; Kumar R
    Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
    Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.